Drug Profile
Ustekinumab biosimilar - DM Bio
Alternative Names: DA 3115; DMB 3115Latest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator Dong-A Socio Holdings; Dong-A ST; Meiji Seika Pharma
- Developer Dong-A Socio Holdings; Meiji Seika Pharma
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Psoriasis
Highest Development Phases
- Preregistration Plaque psoriasis
- Phase III Crohn's disease; Psoriatic arthritis; Ulcerative colitis